Tilade Side Effects
Generic Name: nedocromil
Please note - some side effects for Tilade may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Side Effects of Tilade - for the Consumer
Tilade Aerosol
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Tilade Aerosol:
Seek medical attention right away if any of these SEVERE side effects occur when using Tilade Aerosol:Bad taste in mouth; coughing; headache; nausea; runny nose; sinus inflammation; upper respiratory tract infection.
TopSevere allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty breathing; sudden asthma attack.
Tilade Side Effects - for the Professional
Tilade
Tilade is generally well tolerated. Adverse event information was derived from 6,469 patients receiving Tilade in controlled and open-label clinical trials of 1–52 weeks in duration. A total of 4,400 patients received two inhalations four times a day. An additional 2,069 patients received two inhalations twice daily or another dose regimen. Seventy-seven percent of patients were treated with Tilade for eight weeks or longer.
Of the 4,400 patients who received two inhalations of Tilade four times a day, 2,632 were in placebo-controlled, parallel trials and of these 6.0% withdrew from the trials due to adverse events, compared to 5.7% of the 2,446 patients who received placebo.
The reasons for withdrawal were generally similar in the Tilade and placebo-treated groups, except that patients withdrew due to bad taste statistically more frequently on Tilade than on placebo. Headache reported as severe or very severe, some with nausea and ill feeling, was experienced by 1.0% of Tilade patients and 0.7% of placebo patients.
The events reported with a frequency of 1% or greater across all placebo-controlled studies are displayed for all patients ages 6 years and older who received Tilade or placebo at two inhalations four times daily.
The adverse event profile observed in children ages 6 through 11 was similar to that observed in adults.
| % Experiencing AE | % Withdrawing | |||
| ADVERSE EVENT (AE) | Tilade (N=2632) | Placebo (N=2402) | Tilade | Placebo |
| Special Senses | ||||
| Unpleasant Taste* | 11.6% | 3.1% | 1.6% | 0.0% |
| Respiratory System Disorders | ||||
| Coughing | 8.9% | 10.2% | 1.1% | 1.2% |
| Pharyngitis | 7.6% | 7.5% | 0.5% | 0.4% |
| Rhinitis* | 7.3% | 6.0% | 0.1% | 0.1% |
| Upper Respiratory Infection | 6.7% | 6.3% | 0.1% | 0.2% |
| Sputum Increased | 1.5% | 1.4% | 0.1% | 0.2% |
| Bronchitis | 1.1% | 1.5% | 0.1% | 0.1% |
| Dyspnea | 2.5% | 3.3% | 0.8% | 1.0% |
| Bronchospasm** | 8.4% | 11.8% | 1.4% | 2.0% |
| Sinusitis | 3.3% | 4.1% | 1.1% | 0.0% |
| Respiratory Disorder | 0.8% | 1.1% | 0.0% | 0.0% |
| Gastrointestinal Tract | ||||
| Nausea* | 3.9% | 2.3% | 1.1% | 0.5% |
| Vomiting* | 2.5% | 1.6% | 0.2% | 0.3% |
| Dyspepsia | 1.5% | 1.1% | 0.1% | 0.1% |
| Diarrhea | 1.3% | 1.2% | 0.1% | 0.0% |
| Abdominal Pain* | 1.9% | 1.3% | 0.2% | 0.1% |
| Central and Peripheral Nervous System | ||||
| Dizziness | 0.8% | 1.3% | 0.1% | 0.2% |
| Body as a Whole | ||||
| Headache | 8.1% | 7.5% | 0.4% | 0.2% |
| Chest Pain | 3.6% | 3.8% | 0.7% | 0.5% |
| Fatigue | 1.0% | 0.8% | 0.2% | 0.0% |
| Fever | 3.1% | 3.7% | 0.1% | 0.1% |
| Resistance Mechanism Disorders | ||||
| Infection Viral | 2.4% | 3.2% | 0.1% | 0.1% |
| Vision Disorder | ||||
| Conjunctivitis | 1.1% | 0.7% | 0.0% | 0.1% |
| Skin and Appendages Disorders | ||||
| Rash** | 0.5% | 1.2% | 0.1% | 0.0% |
| * Statistically significant higher frequency on Tilade , p<0.05 | ||||
| **Statistically significant higher frequency on Placebo, p<0.05 | ||||
Other adverse events present at less than the 1% level of occurrence, but that might be related to Tilade administration, include arthritis, tremor, and a sensation of warmth.
In clinical trials with 2,632 patients receiving Tilade , 2 patients (0.08%) developed neutropenia and 3 patients (0.11%) developed leukopenia. Although it is unclear if these reactions were caused by Tilade, in several cases these abnormal laboratory tests returned to normal when Tilade was discontinued.
There have been reports of clinically significant elevation of hepatic transaminases (ALT and AST greater than 10 times the upper limit of the normal reference range in one patient) associated with the administration of Tilade . It is unclear if these abnormal laboratory tests in asymptomatic patients were caused by Tilade.
Cases of bronchospasm immediately following dosing with Tilade have been reported from postmarketing experience. Isolated cases of pneumonitis with eosinophilia (PIE syndrome) and anaphylaxis have also been reported in which a relationship to drug is undetermined.
TopSide Effects by Body System
Gastrointestinal
Gastrointestinal side effects have included unpleasant taste which was reported in approximately 13% of patients receiving nedocromil and resulted in drug withdrawal in up to 3%. Less commonly, nedocromil has caused nausea and vomiting (2% to 4%).
Respiratory
Throat irritation may be relieved by drinking water before and after inhalation of nedocromil. Use of a beta-2 agonist prior to nedocromil inhalation may relieve cough and bronchospasm.
Respiratory side effects have included cough and throat irritation in 6% to 7% of patients treated with nedocromil. Bronchospasm has been induced in 5% of patients.
Nervous system
Nervous system side effects have included headache in up to 6% of patients treated. Less commonly dizziness has been reported.
Hepatic
Hepatic side effects have included elevations of liver function tests (SGPT) in approximately 3% of patients treated with nedocromil.
TopMore resources:
Tilade Inhalation - Includes detailed dosage instructions.
Nedocromil - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
